EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN CHINESE ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: RATIONALE AND DESIGN OF A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE III TRIAL

被引：0

作者：

Zhao, Yan ^{[1
]}

Lu, Qianjin ^{[2
]}

Gao, Xinghua ^{[3
]}

Liu, Lingling ^{[4
]}

Li, Wei ^{[5
]}

Song, Zhiqiang ^{[6
]}

Yao, Zhirong ^{[7
]}

Yao, Xu ^{[8
]}

Hao, Nan ^{[9
]}

Zhang, Jianzhong ^{[1
]}

机构：

[1] Peking Univ, Peoples Hosp, Dept Dermatol, Beijing, Peoples R China

[2] Cent South Univ, Xiangya Hosp 2, Dept Dermatol, Hunan Key Lab Med Epigenom, Changsha, Hunan, Peoples R China

[3] China Med Univ, Hosp 1, NHC Key Lab Immunodermatol, Minist Educ,Key Lab Immunodermatol,Dept Dermatol, Shenyang, Peoples R China

[4] Peking Univ First Hosp, Dept Dermatol, Beijing, Peoples R China

[5] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai, Peoples R China

[6] Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Chongqing, Peoples R China

[7] Shanghai Jiao Tong Univ, Xin Hua Hosp, Sch Med, Dept Dermatol, Shanghai, Peoples R China

[8] Chinese Acad Med Sci & Peking Union Med Coll, Inst Dermatol, Nanjing, Peoples R China

[9] Sanofi, Med Dept, Shanghai, Peoples R China

来源：

ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

PT4

引用

页码：52 / 53

页数：2

共 50 条

[31] Efficacy and Safety of GR1802 in Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Wang, Shangshang
Zhang, Litao
Liang, Yunsheng
Zhang, Shifa
Wang, Jingyan
Man, Xiaoyong
Ji, Chao
Chen, Rixin
Xiang, Guang
Meng, Zudong
Yang, Chunjun
Cheng, Hao
Wang, Qi
Li, Lin-feng
Zhang, Siping
Ding, Yanfeng
Zhu, Quangang
Qin, Lanying
Li, Yumei
Lu, Qianjin
Xia, Li
Cao, Shuanglin
Yu, Chunshui
Duan, Xinsuo
Wu, Liming
Zhang, Chunlei
Jiang, Congjun
Wang, Wei
Xu, Jinhua
DERMATOLOGIC THERAPY, 2025, 2025 (01)
[32] Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Thaci, Diamant
Simpson, Eric L.
Beck, Lisa A.
Bieber, Thomas
Blauvelt, Andrew
Papp, Kim
Soong, Weily
Worm, Margitta
Szepietowski, Jacek C.
Sofen, Howard
Kawashima, Makoto
Wu, Richard
Weinstein, Steven P.
Graham, Neil M. H.
Pirozzi, Gianluca
Teper, Ariel
Sutherland, E. Rand
Mastey, Vera
Stahl, Neil
Yancopoulos, George D.
Ardeleanu, Marius
LANCET, 2016, 387 (10013): : 40 - 52
[33] Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
Ebisawa, Motohiro
Kataoka, Yoko
Tanaka, Akio
Nagao, Mizuho
Laws, Elizabeth
Mortensen, Eric
Nawata, Hisakatsu
Arima, Kazuhiko
Watanabe, Daisuke
Lu, Xin
Maloney, Jennifer
Dubost-Brama, Ariane
Bansal, Ashish
Yahata, Kenji
ALLERGOLOGY INTERNATIONAL, 2024, 73 (04) : 532 - 542
[34] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
Torrelo, A.
Rewerska, B.
Paller, Amy
Prakash, A.
Zhu, D.
Pontes, M.
Wu, Wen-Shuo
Eichenfield, Lawrence F.
Boecker, Ulrike
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
[35] Efficacy and Safety of Lebrikizumab in Combination with Topical Corticosteroids in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 3, Randomized, Placebo-Controlled Trial (ADhere)
Simpson, Eric L.
Gooderham, Melinda
Wollenberg, Andreas
Weidinger, Stephan
Armstrong, April
Soung, Jennifer
Ferrucci, Silvia
Lima, Renata Gontijo
Xu, Wen
Witte, Michael M.
Blauvelt, Andrew
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 61
[36] Efficacy and safety of Soshiho-tang in atopic dermatitis patients with gastrointestinal disorders: A double-blinded, randomized, and placebo-controlled clinical trial
Lee, Ju Hyun
Jo, Eun Heui
Jung, Jee Youn
Kang, Su Jin
Yang, Geum Jin
Shim, Yu Hwa
Park, Min Cheol
JOURNAL OF ETHNOPHARMACOLOGY, 2021, 274
[37] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
Zhao, Yan
Zhang, Jianzhong
Yang, Bin
Li, Jingyi
Ding, Yangfeng
Wu, Liming
Zhang, Litao
Wang, Jinyan
Zhu, Xiaohong
Zhang, Furen
Tao, Xiaohua
Li, Yumei
Zhang, Chunlei
Li, Linfeng
Lu, Jianyun
Diao, Qingchun
Lu, Qianjin
Man, Xiaoyong
Li, Fuqiu
Xia, Xiujuan
Cheng, Hao
Jia, Yingmin
Zhao, Guoqing
Yan, Jinchun
Chen, Bo
CHINESE MEDICAL JOURNAL, 2024, 137 (02) : 200 - 208
[38] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
Zhao Yan
Zhang Jianzhong
Yang Bin
Li Jingyi
Ding Yangfeng
Wu Liming
Zhang Litao
Wang Jinyan
Zhu Xiaohong
Zhang Furen
Tao Xiaohua
Li Yumei
Zhang Chunlei
Li Linfeng
Lu Jianyun
Diao Qingchun
Lu Qianjin
Man Xiaoyong
Li Fuqiu
Xia Xiujuan
Cheng Hao
Jia Yingmin
Zhao Guoqing
Yan Jinchun
Chen Bo
中华医学杂志英文版, 2024, 137 (02)
[39] The efficacy of whey associated with dodder seed extract on moderate-to-severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled clinical trial
Mehrbani, Mehrzad
Choopani, Rasool
Fekri, Alireza
Mehrabani, Mitra
Mosaddegh, Mahmoud
Mehrabani, Mehrnaz
JOURNAL OF ETHNOPHARMACOLOGY, 2015, 172 : 325 - 332
[40] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Carrascosa, Jose Manuel
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Silverberg, Jonathan, I
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188

← 1 2 3 4 5 →